Ignyta Announces Preliminary Results From Phase 1 Clinical Trial For RXDX-101

Ignyta, Inc. announced via press release that preliminary results are in for its Phase I clinical trial of RXDX-101. The oral tyrosine kinase inhibitor is indicated for solid tumors. Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented findings at the International Association for the Study of Lung Cancer (IASLC) 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. Ignyta plans to share the final results later in the year. Based on Dr. Gainor’s presentation, Ignyta filed Form-8-K with the U.S. Securities and Exchange Commission (SEC).

Lung Cancer

Lung cancer originates in the lungs when abnormal cells grow in an uncontrolled manner. Cancer may grow in both lungs or in just one. As the cells grow and multiply, they often mass into a tumor. Abnormal cells and tumors do not provide normal function and interfere with healthy cells. Lung cancer can metastasize and spread to other parts of the body, called secondary lung cancer.

RXDX-101

RXDX-101 is a gene therapy agent, targeting mutant genes, misplaced genes, copies, and variants. The Phase 1 study was a dose escalation study useful in determining the dose for the Phase 2 trial. Eighteen patients participated. Researchers found no toxicities that limit the dose and RXDX-101 shows signs of reducing tumor size. RXDX-101 was licensed from Nerviano Medical Sciences. It is an oral agent used against lung cancer, but it may have promise in treating different kinds of cancer.   

SEC Form-8-K

The SEC requires companies to fill out Form 8-K to provide investors with updates on current and appropriate information in order to make prudent decisions. Information required is “material,” meaning that an investor would consider the information, facts, and data important when considering an investment.  

About Ignyta, Inc.

Ignyta, Inc. is headquartered in San Diego, California. The biotechnology company integrates diagnostics and therapeutics, develops targeted drugs, and customizes cancer treatments. Currently, the company focuses on RXDX-101 and RXDX-102, and its novel Spark discovery programs. Spark-1, Spark-2 and Spark-3 are target validation programs that find agents to alter tumorigenesis. The company is also developing the “Trailblaze Diagnostic Programs,” diagnostic assays to complement its oncology drugs. 

Source:

http://investor.ignyta.com/releasedetail.cfm?ReleaseID=827264